CSRC Approves Yushu Technology's Application for IPO on Shanghai Stock Exchange's Sci-Tech Innovation Board
On July 2nd, the China Securities Regulatory Commission issued a reply approving the initial public offering of shares by Yushu Technology Co., Ltd.
On July 2nd, the China Securities Regulatory Commission released the "Reply on Approving the Initial Public Offering of Shares of Siasun Technology Co., Ltd." It is reported that Siasun Technology plans to list on the Sci-Tech Innovation Board of the Shanghai Stock Exchange, with CITIC SEC as its sponsor institution, aiming to raise 4.202 billion yuan.
According to the prospectus, Siasun Technology is a world-renowned, internationally leading high-performance general Siasun Robot&Automation company, focusing on the research, production, and sales of high-performance general humanoid Siasun Robot&Automation, quadruped Siasun Robot&Automation, Siasun Robot&Automation components, and embodied intelligence models. During the reporting period, the company's main business income was mainly composed of income from quadruped Siasun Robot&Automation and humanoid Siasun Robot&Automation.
With the core technology of general Siasun Robot&Automation and continuous enrichment of the product matrix, the company has led the innovation and scaled landing of the high-performance general Siasun Robot&Automation industry, gaining a major market share in the global markets for quadruped Siasun Robot&Automation and humanoid Siasun Robot&Automation, particularly enjoying high visibility and market share in overseas markets. The company's "high-performance + high cost-effectiveness" strategy has widely covered the research and consumer markets of general Siasun Robot&Automation, promoting its applications in scientific research, education, cultural performances, intelligent services, and other fields, securing a leading market share in the industry.
Related Articles
.png)
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.

US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.
CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.
.png)
US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.

RECOMMEND





